Bowden Christopher 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Jun 9, 2021
Insider Transaction Report
Form 4
Bowden Christopher
Chief Medical Officer
Transactions
- Sale
Common stock
2021-06-07$60.04/sh−4,268$256,232→ 15,487 total - Exercise/Conversion
Common stock
2021-06-08$39.76/sh+6,675$265,398→ 22,162 total - Exercise/Conversion
Stock option (right to buy)
2021-06-08−6,675→ 32,389 totalExercise: $39.76Exp: 2026-02-15→ Common stock (6,675 underlying) - Sale
Common stock
2021-06-08$60.07/sh−6,675$400,939→ 15,487 total - Exercise/Conversion
Common stock
2021-06-07$39.76/sh+4,268$169,696→ 19,755 total - Exercise/Conversion
Stock option (right to buy)
2021-06-07−4,268→ 39,064 totalExercise: $39.76Exp: 2026-02-15→ Common stock (4,268 underlying)
Footnotes (5)
- [F1]This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.10. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.